Compare Booking Holdings Inc (BKNG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs Gilead Sciences, Inc. — how do they compare? Booking Holdings Inc trades at $211.66 (market cap $159.95B), while Gilead Sciences, Inc. trades at $135.72 (market cap $168.35B). The key difference: Booking Holdings Inc and Gilead Sciences, Inc. are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| BKNG | GILD | |
|---|---|---|
Market Cap | $159.95B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $228.83 | $155.80 |
52-Week Low | $154.13 | $110.56 |
Enterprise Value | $163.43B | $191.42B |
Dividend Yield | 0.79% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booking Holdings (BKNG) trades at $211.73, down 0.54% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates at $2.54 versus $2.43 expected, driven by resilient travel demand. Revenue grew to $26.92B in 2025, with a net income margin of 25.53%, while cash flow from operations remains robust at $9.41B. Analyst consensus is strongly bullish with a $239.31 price target.
Outlook is positive given earnings beats and travel recovery, but risks include geopolitical volatility and high valuation multiples. The stock offers growth potential with a wide moat in online travel, though debt levels and competitive pressures warrant monitoring. Institutional sentiment supports upside, with 64% of analysts rating it Buy.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
